jesduvroq daprodustat 1 mg
1 INDICATIONS AND USAGE JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being. JESDUVROQ is not indicated for use: • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. • For treatment of anemia of chronic kidney disease in patients who are not on dialysis. JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. ( 1 ) Limitations of Use Not shown to improve quality of life, fatigue, or patient well-being. Not indicated for use: • As a substitute for transfusion in patients requiring immediate correction of anemia. • In patients not on dialysis.
glaxosmithkline llc
ROUND GREY GS KF
Related Pills
jesduvroq daprodustat 8 mg
glaxosmithkline llc
jesduvroq daprodustat 6 mg
glaxosmithkline llc
jesduvroq daprodustat 4 mg
glaxosmithkline llc
jesduvroq daprodustat 2 mg
glaxosmithkline llc
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied JESDUVROQ tablets contain 1 mg, 2 mg, 4 mg, 6 mg or 8 mg of
DAPRODUSTAT. Tablet Strength Package Configuration and NDC Number Tablet Description and Markings 1 mg 30 count bottle (NDC 0173-0897-13) round, gray, biconvex, film-coated tablets debossed with “GS KF” on one side 100 count blister pack (NDC 0173-0897-56) 2 mg 30 count bottle (NDC 0173-0903-13) round, yellow, biconvex, film-coated tablets debossed with “GS V7” on one side 100 count blister pack (NDC 0173-0903-56) 4 mg 30 count bottle (NDC 0173-0906-13) round, white, biconvex, film-coated tablets debossed with “GS 13” on one side 100 count blister pack (NDC 0173-0906-56) 6 mg 30 count bottle (NDC 0173-0911-13) round, pink, biconvex, film-coated tablets debossed with “GS IM” on one side 100 count blister pack (NDC 0173-0911-56) 8 mg 30 count bottle (NDC 0173-0914-13) round, orange, biconvex, film-coated tablets debossed with “GS 5E” on one side 100 count blister pack (NDC 0173-0914-56) Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). [See USP Controlled Room Temperature].
More pills like ROUND GS KF